title: Author reply.
authors.affiliation: Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
authors.forename: J S
authors.initials: JS
authors.lastname: Fok
authors.affiliation: Department of Clinical Immunology and Allergy, Campbelltown Hospital, Sydney, New South Wales, Australia.|University of Western Sydney, Sydney, New South Wales, Australia.
authors.forename: C H
authors.initials: CH
authors.lastname: Katelaris
authors.affiliation: School of Medicine, University of Queensland, Brisbane, Queensland, Australia.|Department of Emergency Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
authors.forename: A F
authors.initials: AF
authors.lastname: Brown
authors.affiliation: Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
authors.forename: W B
authors.initials: WB
authors.lastname: Smith
mesh_terms: D000799:Angioedema / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001920:Bradykinin / Q000031:analogs & derivatives*; D065094:Bradykinin B2 Receptor Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D065094:Bradykinin B2 Receptor Antagonists; D001920:Bradykinin